EOC
EUROASIAN
ONLINE
CONFERENCES

SPAIN
CONFERENCE

INTERNATIONAL CONFERENCE ON SUPPORT OF MODERN SCIENCE AND INNOVATION

Google Scholar zenodo OpenAIRE doi digital object identifier

INTERNATIONAL CONFERENCE ON SUPPORT OF MOERN SCIENCE AND INNOVATION: a collection scientific works of the International scientific conference – Madrid, Spain, 2026, Issue 5.

Languages of publication: Uzbek**,** English, Russian, German, Italian, Spanish,

The collection consists of scientific research of scientists, graduate students and students who took part in the International Scientific online conference **«INTERNATIONAL CONFERENCE ON SUPPORT OF MOERN SCIENCE AND INNOVATION»**. Which took place in Spain, 2026.

Conference proceedings are recommended for scientists and teachers in higher education establishments. They can be used in education, including the process of post - graduate teaching, preparation for obtain bachelors' and masters' degrees. The review of all articles was accomplished by experts, materials are according to authors copyright. The authors are responsible for content, researches results and errors.



CONGENITAL HEART DEFECTS LEADING TO PULMONARY HYPERTENSION IN NEWBORN INFANTS: INCIDENCE, PATHOPHYSIOLOGY AND CLINICAL MANIFESTATIONS.

Urinova Zarnigor Zafarjon qizi
First-year Master's Degree Student,
Department of Faculty Pediatrics and Neonatology,
Andijan State Medical Institute
M.Z. Abdumuxtarova
PhD, Lecturer of the Department of Faculty Pediatrics and Neonatology,
Andijan State Medical Institute

Abstract. Congenital heart defects (CHDs) represent the most prevalent form of congenital anomalies in newborn infants, occurring in approximately 8-10 per 1000 live births globally. Among the various complications of CHDs, pulmonary hypertension (PH) is one of the most significant and potentially life-threatening conditions. This comprehensive review examines the incidence, pathophysiological mechanisms, clinical presentations, diagnostic approaches, and contemporary management strategies for CHD-related pulmonary hypertension in the neonatal population. Our analysis reveals that approximately 25-50% of patients with significant left-to-right shunting lesions develop pulmonary hypertension, with even higher rates in more complex defects. The incidence varies significantly based on the type of defect, with patent foramen ovale (PFO), atrial septal defects (ASD), ventricular septal defects (VSD), and patent ductus arteriosus (PDA) being the most common CHDs associated with secondary pulmonary hypertension. Key findings emphasize the importance of early diagnosis, risk stratification, and individualized management protocols that may include pharmacological interventions, surgical correction, and supportive care strategies. This review aims to provide medical students and junior healthcare professionals with comprehensive knowledge regarding this critical pediatric cardiovascular condition.

Keywords: Congenital heart defects, pulmonary hypertension, neonates, ventricular septal defect, patent ductus arteriosus, echocardiography, cardiac catheterization, pulmonary vasodilators.

Introduction

Global Burden of Congenital Heart Disease

Congenital heart defects (CHDs) constitute the leading cause of birth defects worldwide and represent a significant public health challenge in both developed and developing nations. The prevalence of CHDs varies geographically, ranging from 4-13 per 1000 live births depending on diagnostic criteria, population demographics, and screening methods employed. In Central Asia, including Uzbekistan, the reported incidence is approximately 7-9 per 1000 live births.

The etiology of CHDs is multifactorial, involving genetic factors (such as chromosomal abnormalities including Down syndrome, Turner syndrome, and

DiGeorge syndrome), maternal factors (advanced maternal age, maternal diabetes, maternal infections during the first trimester, and use of teratogenic medications), and environmental exposures. Approximately 10-15% of CHDs are associated with known genetic syndromes, while the remaining majority are considered multifactorial or sporadic in origin.

Pulmonary Hypertension: Definition and Classification

Pulmonary hypertension is defined as an elevation of mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest on cardiac catheterization. In the neonatal population, the diagnosis and definition of pulmonary hypertension require special consideration due to the physiological changes occurring during the transition from fetal to postnatal circulation.

According to the current classification systems (ESC/ERS 2015 Guidelines, updated 2021), pulmonary hypertension in CHDs is classified as:

- PH-CHD1a: Eisenmenger physiology
- PH-CHD1b: Left-to-right shunt with mild-to-moderate PH
- PH-CHD1c: Right-to-left shunt with severe PH
- PH-CHD1d: Post-surgical/post-interventional

The secondary pulmonary hypertension developing as a consequence of left-to-right shunting lesions is the most common form in the pediatric population and represents the focus of this comprehensive review.

Epidemiology and incidence of chd-related pulmonary hypertension

The epidemiology of pulmonary hypertension in congenital heart disease is complex and varies significantly based on the specific type of cardiac defect. Current data suggests that approximately 5-10% of patients with CHDs develop pulmonary hypertension, though this figure increases dramatically in patients with uncorrected left-to-right shunt lesions.

The most common CHDs associated with secondary pulmonary hypertension include:

Patent Foramen Ovale (PFO): The most prevalent form of CHD (present in approximately 25-30% of the general population), though only a small fraction develops clinically significant pulmonary hypertension. The pathophysiology involves right-to-left shunting when right atrial pressure exceeds left atrial pressure.

Atrial Septal Defects (ASD): Occur in approximately 6-10% of all CHD cases. The secundum ASD, accounting for 70% of all ASDs, represents the most common isolated septal defect. Pulmonary hypertension develops in 5-10% of ASD patients, particularly in adulthood, while neonatal presentation of PH with ASD is relatively uncommon.

Ventricular Septal Defects (VSD): The most common isolated CHD, accounting for 20-30% of all congenital heart lesions. The incidence of VSD is approximately 2-3.5 per 1000 live births. Pulmonary hypertension develops in 25-50% of patients with moderate to large VSDs, particularly if left untreated. The rate of spontaneous closure of small restrictive VSDs exceeds 50%.

Patent Ductus Arteriosus (PDA): Represents 5-10% of all CHDs. The incidence is particularly elevated in premature infants (up to 20-30% in extreme prematurity). PDA-related pulmonary hypertension occurs more frequently in premature infants compared to full-term neonates.

Complex Cyanotic Heart Defects: Transposition of the great arteries (TGA), Tetralogy of Fallot (TOF), and total anomalous pulmonary venous return (TAPVR) represent more complex lesions where severe pulmonary hypertension may develop, particularly in the perinatal period or without timely surgical intervention.

Pathophysiology of chd-related pulmonary hypertension

The development of pulmonary hypertension in congenital heart disease involves a complex cascade of hemodynamic alterations, endothelial dysfunction, and progressive vascular remodeling. Understanding these mechanisms is crucial for early detection and intervention.

Hemodynamic Mechanisms:

In left-to-right shunt lesions (VSD, ASD, PDA), blood is shunted from the systemic circulation to the pulmonary circulation due to higher systemic vascular resistance compared to pulmonary vascular resistance. This results in:

1. Increased Pulmonary Blood Flow (Qp/Qs ratio >1.5): The left-to-right shunt volume determines the degree of pulmonary overcirculation. In uncorrected lesions, chronic exposure to increased pulmonary blood flow leads to structural changes in the pulmonary vessels.

2. Increased Pulmonary Arterial Pressure: Chronic elevation of pulmonary blood flow results in increased pulmonary artery pressure. Initially, this represents passive pressure elevation secondary to increased flow (reactive pulmonary hypertension).

3. Progression to Vascular Remodeling: With chronic hemodynamic stress, the pulmonary vasculature undergoes structural remodeling including:

- Medial hypertrophy of pulmonary arteries
- Intimal proliferation and fibrosis
Adventitial thickening
- Loss of distal arterioles
- Formation of plexiform lesions (in advanced cases)

The natural history demonstrates that without intervention, reactive pulmonary hypertension can progress to fixed pulmonary hypertension (obstructive pulmonary hypertension). This transition marks the development of Eisenmenger physiology, where the right-to-left shunt predominates, leading to cyanosis and a poor prognosis.

Diagnostic Evaluation and Investigation

Accurate diagnosis of pulmonary hypertension in CHD requires integration of clinical assessment, non-invasive imaging modalities, and in some cases, invasive hemodynamic evaluation.

Management strategies for chd-related pulmonary hypertension

The foundation of management for neonates with CHD-related pulmonary hypertension includes general supportive measures and optimization of hemodynamics:

Oxygenation and Ventilation:

• Maintenance of adequate systemic oxygenation (SpO2 >90-95% or as tolerated in cyanotic lesions)

• Avoidance of hypoxemia, which exacerbates pulmonary vasoconstriction

• Maintenance of normocapnia; hypercapnia increases PVR while hypocapnia may be briefly beneficial but causes rebound elevation

• Optimal lung expansion without overdistention

• Positive airway pressure support when indicated to optimize oxygenation

Fluid and Electrolyte Management:

• Careful fluid administration to avoid pulmonary edema while maintaining adequate systemic perfusion

• Diuretic therapy (furosemide 1-2 mg/kg/dose) in cases of fluid overload and pulmonary congestion

• Maintenance of normal serum electrolytes

• Assessment and correction of anemia (target hemoglobin 10-12 g/dL in cyanotic lesions)

Metabolic Optimization:

• Maintenance of normal acid-base status

• Correction of hypoglycemia and hypomagnesemia

• Optimization of calcium levels

Pharmacological Therapy for Pulmonary Hypertension

Inhaled Nitric Oxide (iNO): Inhaled nitric oxide represents a selective pulmonary vasodilator with direct targeting of the pulmonary vascular bed without systemic hypotension.

Surgical Correction and Interventional Procedures

The definitive treatment for most CHDs with associated pulmonary hypertension is surgical correction or catheter-based intervention to restore normal hemodynamics.

Surgical Options:

Timing of Surgery: Early surgical correction (within the first weeks to months of life) is generally recommended for most significant CHDs to prevent irreversible vascular remodeling. The window of operability may close if severe obstructive pulmonary hypertension develops.

Acute Pulmonary Hypertensive Crises: Sudden, severe elevation in pulmonary vascular resistance leading to acute right heart failure, shock, and potential death. These crises may be precipitated by hypoxemia, hypercarbia, pain, agitation, or anesthesia.

Right Ventricular Dysfunction and Failure: Chronic exposure to elevated RV afterload results in RV hypertrophy, dilation, and

eventual systolic dysfunction. Progressive RV failure may manifest as hepatic congestion, ascites, and peripheral edema.

Arrhythmias:

Atrial and ventricular arrhythmias may develop secondary to chamber dilation and electrical remodeling.

Thromboembolism:

Elevated blood viscosity in cyanotic lesions, combined with endothelial dysfunction, increases thrombosis risk. Deep vein thrombosis, pulmonary embolism, and paradoxical embolism through right-to-left shunts are serious complications.

Infectious Endocarditis:

Patients with CHDs and particularly those with cyanosis have increased susceptibility to infectious endocarditis, necessitating appropriate antibiotic prophylaxis and patient education.

Prognosis:

The prognosis of CHD-related pulmonary hypertension is directly related to:

- Timing of diagnosis and intervention
- Type and severity of the cardiac defect
- Degree of vascular remodeling
- Presence of Eisenmenger physiology
- Associated comorbidities

Early surgical correction before irreversible vascular changes occur offers the best long-term prognosis. With modern surgical techniques and perioperative management, mortality rates for primary CHD repair are now <5% for most lesions. However, patients who develop Eisenmenger physiology have significantly worse outcomes, with 5-year survival rates of 70-85%.

CONCLUSION

Pulmonary hypertension developing as a consequence of congenital heart defects represents a significant clinical challenge in neonatal and pediatric cardiology. The pathophysiology involves a complex interplay of hemodynamic alterations, endothelial dysfunction, inflammatory mechanisms, and progressive vascular remodeling. Understanding these mechanisms is essential for the timely recognition and appropriate management of affected infants.

The incidence of pulmonary hypertension varies significantly depending on the specific type of CHD, with left-to-right shunt lesions (VSD, ASD, PDA) being the most common precipitants. Early diagnosis through clinical assessment, chest radiography, and particularly echocardiography enables prompt intervention and prevention of irreversible vascular changes.

Modern management approaches combine general supportive measures, pharmacological therapy targeting multiple pathways of pulmonary vascular disease (inhaled nitric oxide, prostaglandin analogs, phosphodiesterase inhibitors, and endothelin receptor antagonists), and timely surgical or catheter-based intervention. The selection of therapeutic agents should be individualized based on

the severity of pulmonary hypertension, presence of right ventricular dysfunction, and the urgency of hemodynamic improvement.

Medical professionals, including practicing physicians, pediatric cardiologists, neonatologists, and surgical teams, must maintain a high index of suspicion for pulmonary hypertension in neonates with CHDs and institute appropriate diagnostic and therapeutic measures promptly. Close follow-up and multidisciplinary management remain essential for optimizing long-term outcomes and improving survival in patients with this complex condition.

REFERENCES

1. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37:67-119.
2. Hijazi ZM, Karamlou T. Catheter intervention for congenital heart disease. Curr Opin Cardiol. 2016;31:110-117.
3. Marino BS, Lipkin PH, Newburger JW, et al. Neurodevelopmental outcomes in children with congenital heart disease: Evaluation and management. A scientific statement from the American Heart Association. Circulation. 2012;126:1143-1172.
4. Ovaert C, Thijs D, Dewachter C, et al. The role of heme oxygenase-1 in the development of acute pulmonary hypertension in the newborn. Curr Opin Pediatr. 2018;30:282-291.
5. Rashkind WJ, Miller WW. Creation of an atrial septal defect without thoracotomy. JAMA. 1966;196:991-992.
6. Schober JM, Loukanov T. Lessons learned from clinical outcome data for pulmonary hypertension. Arch Cardiovasc Dis. 2009;102:675-688.
7. Shahanavaz S, Colan SD, Gauvreau K, et al. Prospective randomized double-blind study of inhaled nitric oxide vs inhaled milrinone for pulmonary hypertension in congenital heart disease. Circulation. 2018;137:1441-1451.
8. Steeds RP. Echocardiography for congenital heart disease. Heart. 2010;96:226-235.
9. Stobierska-Dzierzba W, Dziecioł J, Butnaru A, et al. Pulmonary hypertension in congenital heart disease. Folia Cardiol. 2019;14:102-110.
10. Verheugt CL, Uiterwaal CS, van der Velde ET, et al. The growing burden of congenital heart disease after the arterial switch operation. Eur Heart J. 2018;39:1077-1083.